Treatment with Gocovri (amantadine) reduced Parkinson’s dyskinesia — involuntary, jerky movements — and so-called “off” episodes, leading to longer periods of controlling motor symptoms, Phase 3 clinical trial results show. Parkinson’s motor fluctuations (off episodes) occur when the benefits of treatments such as levodopa wear off and symptoms…
News
A new software can predict with an accuracy of 96 percent the form of Parkinson’s disease and future symptoms that a patient may experience. The software was the result of a collaboration between researchers at Peter the Great St. Petersburg Polytechnic University (SPbPU), the Institute of Experimental Medicine,…
A four-man crew from Britain is hoping to increase understanding of Parkinson’s disease by rowing across the Indian Ocean in an attempt to break a world record. Robin Buttery, Barry Hayes, James Plumley, and skipper Billy Taylor are planning to row for 1,920 hours non-stop, for 65 days straight, all…
Sunovion Pharmaceuticals’ apomorphine sublingual under-the-tongue film (APL-130277) — now under review for approval — significantly improved motor fluctuations, or off episodes, in Parkinson’s patients in Phase 3 clinical trial, results show. The double-blind pivotal study, (NCT02469090), evaluated the efficacy and safety of APL-130277 as a fast-acting oral treatment for…
A new device that can increase the production of viable neural stem cells may change the landscape of neural stem cell therapies as potential strategies for neurodegenerative and chronic diseases, including Parkinson’s and Alzheimer’s. The invention, developed by a team at Hong Kong Baptist University (HKBU), was recently…
News
Deep Brain Stimulation May Increase Levels of Inflammatory Factors in Parkinson’s, Study Suggests
Deep brain stimulation (DBS) may increase the levels of hepcidin — a hormone associated with iron accumulation and inflammation in the brain — in Parkinson’s disease patients, according to a small Polish study. The study, “Higher serum levels of pro-hepcidin in patients with Parkinson’s disease treated with…
The U.S. Food and Drug Administration granted Voyager Therapeutics’ gene therapy candidate VY-AADC regenerative medicine advanced therapy (RMAT) designation for the treatment of therapy-resistant motor fluctuations in Parkinson’s patients. The RMAT designation, recently created by the FDA, is given to regenerative medicine products intended to treat, modify, reverse,…
More than half of Parkinson’s patients who have been treated with a dopamine agonist may develop impulse control disorders over time, according to recent research. The study, “Longitudinal analysis of impulse control disorders in Parkinson disease,” was published in the journal Neurology. Impulse control disorders are characterized…
The Michael J. Fox Foundation (MJFF) recently held a summit to discuss the unmet needs and challenges for advancing therapies to slow down or halt Parkinson’s disease. The event, which took place in New York, was attended by representatives from 20 companies, a number of academic centers and research organizations, and…
A new tool called cardiopulmonary coupling could be used to effectively evaluate sleep quality in Parkinson’s disease patients, who often experience sleep disorders, according to a study. The study, “Assessment of sleep quality using cardiopulmonary coupling analysis in patients with Parkinson’s disease,” was published in Brain and Behavior.
Recent Posts
- Pirepemat shows promise in trial for reducing risk of falls in Parkinson’s
- When it comes to Parkinson’s, hope is not a plan, but urgent action is
- My uncle’s Parkinson’s progression changed some things, but not others
- Gene therapy shows promise for early-onset Parkinson’s in lab study
- New study finds early Parkinson’s signals in blood years before symptoms